IPP Bureau
DuPont adds sterile packaging capacity of healthcare manufacturing site in Costa Rica
By IPP Bureau - June 07, 2025
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia
By IPP Bureau - June 07, 2025
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC
By IPP Bureau - June 07, 2025
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
NPPA fixes retail prices for 41 drug combinations
By IPP Bureau - June 06, 2025
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
.jpg "Thyrocare opens diagnostic lab in Srinagar")
Thyrocare opens diagnostic lab in Srinagar
By IPP Bureau - June 06, 2025
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy
By IPP Bureau - June 06, 2025
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Sun Pharma discontinue development of SCD-044 drug after trial disappointment
By IPP Bureau - June 05, 2025
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
By IPP Bureau - June 05, 2025
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Allarity announces enrolment of first patient in phase 2 clinical trial protocol of Stenoparib in advanced ovarian cancer
By IPP Bureau - June 05, 2025
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
UK MHRA approves aumolertinib to treat non-small cell lung cancer
By IPP Bureau - June 05, 2025
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Sanofi exercises license extension option to Nurix’s STAT6 program
By IPP Bureau - June 04, 2025
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Amyris expands precision fermentation line in Brazil
By IPP Bureau - June 04, 2025
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
